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Purpose: The purpose of this study was to estimate the presence of metabolic syndrome (MS) 
in a group of children and adolescents with a body mass index (BMI) above the 85th percentile 
for their age and sex in Qazvin Province, Iran; to evaluate the relationship between obesity and 
metabolic abnormalities; and to compare two proposed definitions of MS.
Patients and methods: The study was conducted on 100 healthy subjects aged between 6 and 
16 years (average age, 10.52 ± 2.51 years) with a high BMI for their age and sex.   Fifty-eight 
percent of subjects were female. Physical examination including evaluation of weight, height, 
BMI, and blood pressure measurement was performed (“overweight” was defined as a BMI 
between the 85th and 95th percentiles for children of the same age and sex; “obese” was 
defined as a BMI over the 95th percentile for children of the same age and sex). Blood levels 
of glucose, insulin, total cholesterol, high-density lipoprotein cholesterol, low-density lipopro-
tein   cholesterol, triglycerides, and uric acid were measured after a 12-hour overnight fast. The 
authors used and compared two definitions of MS: the National Cholesterol Education Program’s 
Adult Treatment Panel III (NCEP ATP III) criteria and a modified definition by Weiss et al. 
Variables were compared using the Student’s t-test and chi-square and Mann-Whitney U tests, 
and agreement between the two definitions was analyzed using kappa values.
Results: The subjects had a mean BMI of 26.02 ± 4.38 and 80% had obesity. Insulin resistance 
was found in 81% of the study population. MS was present in ten (50%) of the overweight 
and 53 (66.2%) of the obese subjects using the NCEP ATP III criteria. MS was present in five 
(25%) of the overweight and 34 (42.5%) of the obese subjects using the definition by Weiss et al. 
The overall kappa value for the two definitions of MS was 0.533. There were no statistically 
significant differences between the two definitions of MS in participants.
Conclusion: The prevalence of MS in children and adolescents depends on the criteria chosen 
and their respective cutoff points. The NCEP ATP III criteria, the parameters of which include 
higher cutoff values for high-density lipoprotein cholesterol and triglycerides, detected the 
higher prevalence and therefore the NCEP ATP III criteria are able to diagnose a larger number 
of children and adolescents at metabolic risk.
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Introduction
The prevalence of childhood obesity has more than doubled in the last 2 decades in 
many countries and it is now considered a serious medical and public health problem 
globally.1–3 Obesity causes sleep apnea and psychological problems in childhood and 
it increases the risk of cardiovascular disease, diabetes, hypertension, dyslipidemia, 
osteoarthritis, and cancer in future life.1,4,5
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Hanefeld and Leonhardt6 first discussed metabolic 
  syndrome (MS) in 1981. In 1988, Reaven7 described it as a 
link between insulin resistance (IR) and hypertension, dys-
lipidemia, type 2 diabetes, and other metabolic abnormalities 
that are associated with an increased risk of atherosclerotic 
cardiovascular disease in adulthood.7
It has been suggested that MS may originate in the 
uterus.8,9 Genetic factors or adverse events in early life or 
a sedentary lifestyle may cause MS and its complications, 
especially in non- European populations.10–12 IR has been rec-
ognized in the pathogenesis of the syndrome, and childhood 
obesity is the most common feature associated with IR.7,13
Few studies have estimated the prevalence of MS in 
children and adolescents,14 and diagnostic criteria have not 
been standardized.15–17 Definitions agree on the essential 
components of the syndrome but there are differences in some 
diagnostic criteria.13,18 Although, the accuracy of present MS 
definitions is under debate, it seems that MS screening in the 
overweight and obese pediatric population and comparison 
of different suggested criteria is essential.
The aim of this study was to estimate the presence of 
MS in a group of children and adolescents with a BMI 
above the 85th percentile for their age and sex in Qazvin 
Province, Iran, to evaluate the relationship between obesity 
and metabolic abnormalities, and to compare two proposed 
definitions of MS.
Material and methods
This study was conducted with 100 children and adolescents 
(calculated sample size was 83 persons, considering Z = 1.96, 
expected prevalence or proportion was 31.9%, and precision 
was 0.07) living in Qazvin Province. Qazvin is a city located 
about 150 km west of Tehran, the capital of Iran. Overweight 
and obese subjects were referred to the authors’ pediatric 
endocrine clinic by their general practitioner or primary care 
pediatric consultant between 2009 and 2010.
The subjects were healthy, aged between 6 and 16 years 
old (average age, 10.52 ± 2.51 years), and had a body mass 
index (BMI) above the 85th percentile for their age and sex. 
Fifty-eight percent of the subjects were female. “Overweight” 
was defined as a BMI between the 85th and 95th percentiles 
for children of the same age and sex; “obese” was defined as a 
BMI over the 95th percentile for children of the same age and 
sex.19 Subjects with diabetes and who were under treatment 
with medication that influences blood pressure (BP), blood 
glucose, or lipid metabolism were excluded from the study. 
Children with secondary obesity due to drugs or endocrine 
or genetic disorders were also excluded from the study. 
The ethics committee of Qazvin University of Medical 
  Sciences approved the study. Written informed consent from 
both the participants and their parents was obtained.
Demographic characteristics were noted in a questionnaire 
given to participants. A pediatric endocrinologist performed 
the physical examination of the subjects, which included an 
evaluation of weight, height, BMI, and BP measurement, with 
special attention given to the existence of acanthosis nigricans, 
defined as the thickening and darkening of the upper layers of 
the skin of the posterior neck, axilla, elbows, or knees.20
Height was measured twice, while subjects were barefoot, 
to an accuracy of ±0.1 cm. Weight was measured twice, while 
subjects were lightly dressed, to an accuracy of ±0.1 kg. BMI 
was calculated by dividing the weight (kg) by the square of 
the height (m). Waist circumference (WC) was measured to 
an accuracy of ±0.2 cm with a nonelastic measuring tape. WC 
was measured at a point halfway between the lower border of 
the thorax and the iliac crest at the end of expiration.21
BP was measured with a mercury sphygmomanometer 
after a 5-minute rest. Systolic and diastolic BPs were taken 
twice, with the patient sitting down. Appropriately sized BP 
cuffs were used, with the width of the cuff being 40% of the 
mid-arm circumference, and with cuff bladders covering 
80%–100% of the arm circumference and approximately two-
thirds of the length of the upper arm, without ov  erlapping. 
The readings at the first and fifth phases of Korotkoff sounds 
were considered as the systolic BP and the diastolic BP, 
respectively.22 Elevated systolic or diastolic BP was defined 
in two ways, on the basis of the definitions of MS, as a value 
exceeding the 90th percentile in NCEP ATP III definition   
or the 95th percentile in Weiss et al’s definition12 for age, 
sex and height.
Venous blood samples were obtained from subjects after a 
12-hour overnight fast. Blood levels of glucose, insulin, total 
cholesterol, high-density lipoprotein cholesterol (HDL-C), 
low-density lipoprotein cholesterol (LDL-C), triglycerides 
(TGs), and uric acid were measured in all patients. All bio-
chemical measurements were performed in one laboratory.
A Selectra E analyzer with photometric assay and 
reagent (Parsazmun Company, Tehran, Iran) was used to 
measure fasting blood sugar (FBS); mean intra- and interas-
say coefficients of variation (CVs) were 1.28% and 0.84%, 
respectively. Impaired glucose tolerance was defined as 
a glucose level greater than 140 mg/dL but then less than 
200 mg/dL at 2 hours. Insulin levels were measured by elec-
trochemiluminescence immunoassay using reagent (Roche 
Diagnostics GmbH, Germany). A within-run precision CV 
was 1.9% and total precision CV was 1.45%. The degree of 
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IR was   determined with the use of a homeostatic model, and 
  calculated as the product of the fasting plasma insulin level 
(µlU/mL) and the fasting plasma glucose level (mmol/L), 
divided by 22.5.23 IR was defined as a homeostasis model of 
insulin resistance (HOMA-IR) value of more than 1.775.24
A Selectra E analyzer with photometric assay and reagent 
(Parsazmun Company) was also used to measure choles-
terol, HDL-C, LDL-C, TGs, and serum uric acid; mean 
intra- and interassay CVs for cholesterol were 1.82% and 
1.04%, respectively; for HDL-C, they were 0.73% and 1.8%, 
respectively; for LDL-C, 0.66% and 1.45%, respectively; 
for TGs, 1.82% and 1.04%, respectively; and for serum uric 
acid, 1.18% and 1.13%, respectively.
Since there is no single internationally accepted definition 
of MS for children and adolescents, the authors used and 
compared two definitions. The diagnostic criteria of these 
definitions are shown in Table 1. The first definition used was 
similar to de Ferranti et al’s16 definition of MS, which is based 
on criteria analogous to the National Cholesterol E  ducation 
Program’s Adult Treatment Panel III (NCEP ATP III) 
c  riteria.25 It should be added that de Ferranti et al16 used the 
cutoff of FBS $ 110 mg/dL, but the present authors decided 
to, like recent studies, follow the latest recommendation of the 
American Diabetes Association.11 The National Heart, Lung, 
and Blood Institute’s recommended cutoff point for BP was 
used also. The second definition was a modified definition 
by Weiss et al,12 in which WC and FBS criteria were similar 
to the first definition.
Kolmogorov–Smirnov test was used to examine the 
normality of variables. Data were reported as mean plus or 
minus standard deviation for normally distributed variables 
or as median (minimum to maximum) for non-normally 
distributed variables. Categorical variables were analyzed by 
chi-square test, continuous variables were compared using 
Student’s t-test, and non-normally distributed variables were 
analyzed by Mann-Whitney U test. Agreement between the 
two MS definitions was analyzed using the kappa value, 
which was considered excellent for values greater than 0.81, 
good for values 0.61–0.80, moderate for 0.41–0.60, and 
weak for   values less than 0.4.26 A P-value less than 0.05 was 
considered statistically significant.
Results
The 100 participants had a mean BMI of 26.02 ± 4.38. 
Of the 100 participants, 20 subjects were overweight and 
80 were obese. WC in 81 subjects was more than the upper 
limit of normal, and it ranged from 68 to 118 cm. Waist-to-
hip ratio (WHR) was more than the upper limit of normal 
in all of the females in the study (WHR more than 0.7) 
and in 40 of the males (WHR more than 0.8). WC and 
WHR were significantly different between overweight and 
obese subjects. Eleven overweight subjects and 70 obese 
subjects had a high WC, and 98 subjects had a high WHR. 
Forty-eight subjects had acanthosis nigricans. The ratio 
of LDL-C to HDL-C varied from 1.0 to 10.6 (by a mean 
value of 2.48 ± 1.30). HOMA-IR values ranged from 1.0 
to 20.48. IR was found in 81 subjects. The clinical and 
biochemical characteristics of the population are shown 
in Tables 2 and 3. With respect to all biochemical char-
acteristics, the difference between overweight and obese 
subjects was not significant.
Results by NCEP ATP III criteria
Sixty-three patients met the criteria for MS as defined by the 
NCEP ATP III. It was present in ten (50%) of the overweight 
and 53 (66.2%) of the obese subjects. Hypertension was 
detected in 36% of subjects (34% systolic and 24% diastolic 
hypertension). Values of every component of the definition 
other than WC values were significantly different between 
subjects with and without MS.
The prevalence of each component of MS in both groups 
of subjects is reported in Table 4. High serum levels of TGs, 
cholesterol, LDL-C, uric acid, and FBS were reported in 
74, 31, 17, eight, and twelve children, respectively. The 
low level of HDL-C was 70%. The most frequent compo-
nent of MS was high WC followed by high TGs and low 
HDL-C. MS was not significantly different between males 
and females (P = 0.402).
Table 1 Diagnostic criteria for two definitions of metabolic syndrome
Component Weiss et al12 (any three of these criteria) NCEP ATP III (any three of these criteria)
glucose FPg $ 100 mg/dL FPg $ 100 mg/dL
WC WC $ 75th percentile for age and sex WC $ 75th percentile for age and sex
Tgs Fasting Tgs $ fifth percentile for age and sex Fasting Tgs $ 100 mg/dL
HDL-C HDL , fifth percentile for age and sex HDL ,50 mg/dL (,45 mg/dL in males over 15 years old)
BP SBP/DBP . 95th percentile for age and sex SBP/DBP . 90th percentile for age and sex
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; FPg, fasting plasma glucose; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; 
NCEP ATP III, National Cholesterol Education Program’s Adult Treatment Panel III criteria; SBP, systolic blood pressure; Tgs, triglycerides; WC, waist circumference.
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Table 2 Clinical and laboratory characteristics of subjects
Characteristic Total Overweight (n = 20) Obese (n = 80) P-value
Sex (M/F) 42/58 4/16 38/42 0.022
Age (years)* 10.52 ± 2.51 11.68 ± 2.90 10.23 ± 2.33 0.020
BMI (kg/m2)* 26.02 ± 4.38 22.95 ± 2.56 26.72 ± 4.41 ,0.001
WC (cm)* 85.82 ± 12.77 79.61 ± 7.75 87.24 ± 13.29 0.021
Hip circumference (cm)* 95.44 ± 11.54 92.20 ± 8.23 96.25 ± 12.13 NS
WHR* 0.898 ± 0.068 0.87 ± 0.056 0.904 ± 0.069 0.047
Tgs (mg/dL)** 140 (41–750) 135 (91–750) 146.5 (41–658) NS
Total cholesterol (mg/dL)* 171.09 ± 45.14 181.75 ± 70.4 168.42 ± 36.4 NS
HDL-C (mg/dL)* 43.462 ± 10.99 43.5 ± 11.36 43.45 ± 10.96 NS
LDL-C (mg/dL)* 100.84 ± 34.07 106.75 ± 51.49 99.36 ± 28.39 NS
SBP (mmHg)* 111.60 ± 12.38 109.20 ± 14.01 112.20 ± 12.54 NS
DBP (mmHg)* 67.26 ± 10.28 65.80 ± 10.98 67.62 ± 10.13 NS
Fasting blood glucose (mg/dL)* 90.65 ± 7.91 89 ± 7.38 91.06 ± 8.03 NS
Blood glucose after 2 hours (mg/dL)* 102.02 ± 22.05 94.5 ± 27.02 103.9 ± 20.4 NS
Fasting insulin (µIU/mL)** 16.3 (5.7–76.8) 15.2 (6.1–48.1) 17.25 (5.7–76.8) NS
Insulin after 2 hours (µIU/mL)** 58.5 (6.2–351) 55.8 (18.2–248.2) 60.7 (6.2–351) NS
HOMA-IR** 3.57 (1–20.48) 2.96 (1–10.22) 3.87 (1.05–20.48) NS
IR (n) 81 16 65 NS
Uric acid (mg/dL)* 5.2 ± 1.17 5.06 ± 1.1 5.24 ± 1.19 NS
Notes: *Data presented as mean plus or minus standard deviation; **data presented as median (minimum to maximum).
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model of insulin resistance; 
IR,  insulin  resistance;  LDL-C,  low-density  lipoprotein  cholesterol;  NS,  not  significant;  SBP,  systolic  blood  pressure;  TGs,  triglycerides;  WC,  waist  circumference; 
WHR, waist-to-hip ratio.
In spite of fasting insulin, HOMA-IR was not statistically 
different between subjects with and subjects without MS. 
Overall, MS was observed in 64.2% of patients with IR, 
compared with 57.9% for those without, but the difference 
was not significant.
Results by Weiss et al’s12 definition
Thirty-nine patients met the criteria for MS as defined by 
Weiss et al.12 It was present in five (25%) of the overweight 
and 34 (42.5%) of the obese subjects. Hypertension was 
detected in 34% of subjects (33% systolic and 23% diastolic 
hypertension). Values of every component of the definition 
between subjects with and without MS were significantly 
different. In addition, BMI and hip circumference values 
were statistically different between these two groups.
The most frequent component of MS was high WC, 
  followed by high TGs and then hypertension (see Table 4). 
MS was not significantly different between males and females 
(P = 0.304). Fasting insulin and HOMA-IR values were 
statistically different between subjects with and subjects 
without MS. Overall, MS was observed in 43.6% of patients 
with IR, as compared with 26.3% for those without, but the 
difference was not significant.
In both definitions, subjects with MS had lower insulin 
sensitivity parameters and higher oral glucose tolerance test 
and uric acid levels than those subjects without MS, but the 
difference was not significant. The values of every component 
of the two MS definitions were compared among subjects 
diagnosed with MS but no significant differences were found 
(FBS, 0.22; WC, 0.86; HDL-C, 0.59; TGs, 0.628; BP, 0.103). 
When the frequency of the different components of MS in 
overweight and obese patients was compared, there were no 
significant differences found with respect to hypertension, 
low HDL-C, high TGs, and FBS.
As expected, abdominal obesity was the most frequent 
criterion (81%) in overweight and obese children and ado-
lescents, followed by a high TG level.
The overall kappa value for the two definitions of MS was 
0.533. To examine possible causes of moderate agreement 
between the definitions, the authors compared agreement 
between the criteria of the two MS definitions in the study 
population. The kappa values were 0.308 and 0.728 for 
HDL-C and TGs, respectively.
Discussion
MS is one of the most important and serious challenges 
in global health in the modern world. The authors found a 
high prevalence of MS (42.5%) in the obese children, while 
prevalence was 25% in the overweight children. Abdominal 
obesity, a criterion of MS, also presented in a significant por-
tion of the obese and overweight children. Among children 
and adolescents of Caucasian origin in Italy, the prevalence 
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Table 3 Clinical and laboratory characteristics of subjects for each group of criteria
Characteristic NCEP ATP III Weiss et al12
MS (n = 63) No MS (n = 37) P-value MS (n = 39) No MS (n = 61) P-value
Sex (M/F) 24/39 18/19 NS 19/20 24/37 NS
Age (year)* 10.72 ± 2.49 10.19 ± 2.50 NS 11.06 ± 2.19 10.07 ± 2.58 NS
BMI (kg/m2)* 26.43 ± 3.81 25.27 ± 5.24 NS 27.45 ± 3.77 25.06 ± 4.51 0.008
WC (cm)* 87.31 ± 10.17 83.07 ± 16.37 NS 89.80 ± 9.92 83.15 ± 13.82 0.011
Hip circumference (cm)* 0.90 ± 0.05 93.42 ± 13.51 NS 99.07 ± 8.96 92.64 ± 12.59 0.007
WHR* 0.902 ± 0.069 0.89 ± 0.08 NS 0.90 ± 0.05 0.893 ± 0.075 NS
Tgs (mg/dL)** 175 (91–750) 92 (41–177) ,0.001 184 (110–750) 118.5 (41–259) ,0.001
Total cholesterol (mg/dL)* 180.06 ± 48.47 154.79 ± 35.22 0.009 183.79 ± 52.92 162.74 ± 38.38 0.025
HDL-C (mg/dL)* 40.67 ± 9.16 48.91 ± 12.32 0.001 39.59 ± 11.02 46.22 ± 10.31 0.003
LDL-C (mg/dL)* 105.77 ± 37.28 92.22 ± 27.01 NS 107.82 ± 40.78 96.45 ± 29.4 NS
SBP (mmHg) 31 (49.2) 3 (8.1) 0.000 25 (64.1) 8 (13.8) 0.000
DBP (mmHg) 23 (36.5) 1 (2.27) 0.000 19 (48.7) 4 (6.9) 0.000
Hypertension (n) 33 (52.4) 3 (8.1) 0.000 27 (69.2) 8 (12) 0.000
Fasting blood glucose (mg/dL)* 91.98 ± 7.66 88.35 ± 8.20 0.032 93.89 ± 7.52 88.56 ± 7.66 0.001
Blood glucose after 2 hours (mg/dL)* 104.65 ± 17.11 97.54 ± 28.29 NS 105.38 ± 18.76 99.68 ± 24.30 NS
Fasting insulin (µIU/mL)** 19.1 (6.1–76.8) 11.8 (5.7–60) 0.048 21.5 (6.1–76.8) 12.6 (5.7–60) 0.001
Insulin after 2 hours (µIU/mL)** 67.15 (9.2–351) 44 (6.2–138.7) 0.001 62 (9.2–351) 56.9 (6.2–211.3) NS
HOMA-IR** 4.28 (1–20.48) 2.96 (1.05–19.77) NS 4.88 (1–20.48) 3.11(1.05–19.77) 0.004
IR (n) 52 29 NS 34 47 NS
Uric acid (mg/dL)* 5.33 ± 1.18 4.93 ± 1.12 NS 5.44 ± 1.10 5.01 ± 1.19 NS
Notes: *Data presented as mean plus or minus standard deviation; **data presented as median (minimum to maximum).
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model of insulin resistance; 
IR, insulin resistance; LDL-C, low-density lipoprotein cholesterol; MS, metabolic syndrome; NCEP ATP III, National Cholesterol Education Program’s Adult Treatment 
Panel III criteria; NS, not significant; SBP, systolic blood pressure; TGs, triglycerides; WC, waist circumference; WHR, waist-to-hip ratio.
of MS has been reported to be higher in severely obese sub-
jects (31.1%) than moderately obese subjects (12.0%), and 
none of the overweight or normal-weight children studied 
had MS.27 Weiss et al12 also stated that risk of MS increases 
with the degree of obesity.
The prevalence of MS in the present study is higher than 
reported in European countries.18,28–31 The overall prevalence 
of MS in obese children and adolescents has been reported 
as 18% in Spain,13 13.9% in Italy,27 33% in the United 
Kingdom,30 30% in Hispanic children in North America,31 
27.2% in Turkey,32 17.3% in Brazil,33 15.9% in France,34 and 
8.9% in Hungary.35
The differences among studies can originate from the 
different definitions used for childhood MS. In an article on 
obese French children, the frequency of MS was found to 
be 15.9% when using the NCEP ATP III criteria; however, 
the frequency reached 42.5% when using the World Health 
Organization’s insulin resistance syndrome definition.36 In 
the present study, the frequency of MS was 63% when using 
the NCEP ATP III; however, the frequency changed to 39% 
when using Weiss et al’s12 definition. Agreement between the 
definitions used was moderate.
Males usually present higher frequencies of MS.28,37 In 
a large US population study concerning adolescents aged 
12–19 years, MS was found to be about three times more 
prevalent in males.37 Other studies have reported a slightly 
higher prevalence of MS in females than males.38,39 However, 
a significant difference in the prevalence of MS according to 
sex was not found in the present study.
Childhood obesity is associated with cardiovascular 
and metabolic disturbances.40 In the present study, several 
parameters failed to present a significant difference between 
overweight and obese children, except for significantly higher 
WCs in the obese group.
Elevated BP was detected in about one-third of the 
sample. The frequency of elevated BP reported in obese 
children from several European countries (38%)41 and from 
the United States42 is similar to that found in the present study, 
but a higher frequency has been reported in 7- to 9-year-old 
Portuguese schoolchildren.28 High BP has been reported to 
be responsible for MS in 44.7% of Italians and in 66.1% of 
Germans.29 The differences found may be attributable to dif-
ferent dietary habits, such as sodium intake, in populations.
The present authors observed that children with MS pre-
sented a higher BMI and significant differences in clinical 
and biochemical characteristics than those children without 
MS. The reason why some obese children develop MS while 
others do not is still unclear.42
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
59
Two definitions of metabolic syndrome in obese and overweight childrenTherapeutics and Clinical Risk Management 2012:8
T
a
b
l
e
 
4
 
P
r
e
v
a
l
e
n
c
e
 
o
f
 
e
a
c
h
 
c
o
m
p
o
n
e
n
t
 
o
f
 
m
e
t
a
b
o
l
i
c
 
s
y
n
d
r
o
m
e
 
i
n
 
2
0
 
o
v
e
r
w
e
i
g
h
t
 
a
n
d
 
8
0
 
o
b
e
s
e
 
c
h
i
l
d
r
e
n
 
a
n
d
 
a
d
o
l
e
s
c
e
n
t
s
C
o
m
p
o
n
e
n
t
N
C
E
P
 
A
T
P
 
I
I
I
W
e
i
s
s
 
e
t
 
a
l
1
2
T
o
t
a
l
 
(
n
)
O
v
e
r
w
e
i
g
h
t
O
b
e
s
e
P
-
v
a
l
u
e
M
a
l
e
s
 
(
n
)
F
e
m
a
l
e
s
 
(
n
)
P
-
v
a
l
u
e
T
o
t
a
l
 
(
n
)
O
v
e
r
w
e
i
g
h
t
O
b
e
s
e
P
-
v
a
l
u
e
M
a
l
e
s
 
(
n
)
F
e
m
a
l
e
s
 
(
n
)
P
-
v
a
l
u
e
H
i
g
h
 
T
g
s
7
4
1
6
/
2
0
5
8
/
8
0
N
S
2
9
4
5
N
S
6
5
1
1
/
2
0
5
4
/
8
0
N
S
2
8
3
7
N
S
L
o
w
 
H
D
L
-
C
7
0
1
5
/
2
0
5
5
/
8
0
N
S
2
8
4
2
N
S
3
0
6
/
2
0
2
4
/
8
0
N
S
1
2
1
8
N
S
H
i
g
h
 
W
C
8
1
1
1
/
2
0
7
0
/
8
0
0
.
0
0
2
3
3
4
8
N
S
8
1
1
1
/
2
0
7
0
/
8
0
0
.
0
0
2
3
3
4
8
N
S
H
i
g
h
 
S
B
P
/
D
B
P
3
6
8
/
2
0
2
8
/
8
0
N
S
1
3
2
3
N
S
3
4
8
/
2
0
2
8
/
8
0
N
S
1
2
2
2
N
S
H
i
g
h
 
F
B
S
1
2
1
/
2
0
1
1
/
8
0
N
S
7
5
N
S
1
2
1
/
2
0
1
1
/
8
0
N
S
7
5
N
S
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
B
P
,
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
;
 
D
B
P
,
 
d
i
a
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
;
 
F
B
S
,
 
f
a
s
t
i
n
g
 
b
l
o
o
d
 
s
u
g
a
r
;
 
H
D
L
-
C
,
 
h
i
g
h
-
d
e
n
s
i
t
y
 
l
i
p
o
p
r
o
t
e
i
n
 
c
h
o
l
e
s
t
e
r
o
l
;
 
I
R
,
 
i
n
s
u
l
i
n
 
r
e
s
i
s
t
a
n
c
e
;
 
L
D
L
-
C
,
 
l
o
w
-
d
e
n
s
i
t
y
 
l
i
p
o
p
r
o
t
e
i
n
 
c
h
o
l
e
s
t
e
r
o
l
;
 
M
S
,
 
m
e
t
a
b
o
l
i
c
 
s
y
n
d
r
o
m
e
;
 
N
C
E
P
 
A
T
P
 
I
I
I
,
 
N
a
t
i
o
n
a
l
 
C
h
o
l
e
s
t
e
r
o
l
 
E
d
u
c
a
t
i
o
n
 
P
r
o
g
r
a
m
’
s
 
A
d
u
l
t
 
T
r
e
a
t
m
e
n
t
 
P
a
n
e
l
 
I
I
I
 
c
r
i
t
e
r
i
a
;
 
N
S
,
 
n
o
t
 
s
i
g
n
i
fi
c
a
n
t
;
 
S
B
P
,
 
s
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
;
 
T
G
s
,
 
t
r
i
g
l
y
c
e
r
i
d
e
s
;
 
W
C
,
 
w
a
i
s
t
 
c
i
r
c
u
m
f
e
r
e
n
c
e
.
It is well discussed that atherosclerosis begins in   childhood 
and is associated with several MS risk factors. High TG and 
LDL levels and low HDL levels are the most important 
atherogenic factors in children with MS.13,28 In the present 
study, the children with MS presented acanthosis, elevated 
insulin levels, and increased HOMA-IR values. Acanthosis 
nigricans is associated in some cases with   hyperinsulinemia.20 
Children with this characteristic are 1.6 times43 to 4.2 times44 
more prone to having   hyperinsulinemia. Typical areas of 
involvement include the posterior neck, the axilla, the elbows, 
and the knees.
In the current study the difference of insulin level when 
using Weiss et al’s12 definition was significant. IR was found 
in 81% of the study population, while high fasting glycemia 
was 12%. However, high fasting glycemia was not common 
in the subjects. This suggests that an impaired glucose level 
develops later than the other MS components, while IR is 
the earlier abnormality of glucose metabolism in obesity.45 
Actually, excess weight in children and adolescents may 
serve as an accelerator for the onset of type 2 diabetes in 
childhood.28,46 IR seems to be an important pathophysiologic 
factor for MS, becoming more important than overall adi-
posity in the development of the syndrome.28,47 In a recent 
publication, Voss et al48 showed that discrimination between 
overweight and obesity using BMI in young children was 
not a good marker for the prediction of IR or, therefore, for 
the prediction of metabolic risk.
It is recognized that MS in a person’s youth can increase 
risk of developing type 2 diabetes and cardiovascular disease 
in adulthood.49 It is not clear which set of metabolic abnor-
malities will evolve toward a more serious sequel of MS 
or, conversely, which one is potentially more reversible by 
treatment in the future.29 However, it is obvious that treatment 
and prevention of MS in obese youth is necessary. In spite 
of the high prevalence of MS observed in obese youth from 
different studies, there are reports that lifestyle modification 
for young people has led to changes in single components and 
reduction of MS prevalence.50,51 Early diagnosis and treatment 
of weight excess in overweight subjects would prevent the 
health complications of obesity in adulthood.
There is no consensus about the definition of MS in 
children.52 Different MS criteria have been employed for 
different studies in children and adolescents, and the compo-
nents and cutoffs used to diagnose the syndrome have varied 
among the various definitions.12,37,52 Because of the age- and 
sex-dependent changes in several components of MS, adult 
definitions of MS do not apply to children.53 Growth and 
developmental effects during childhood and adolescence 
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make it difficult to choose a distinct cutoff for risk factors.54 
As a result, the prevalence varies according to the definition 
used.52 This point is corroborated by the present study, as the 
authors found a wide range of prevalence between the two 
definitions used.
The major criteria of MS came from the NCEP ATP 
III in 2001. Weiss et al’s12 definition is a slightly modified 
version of the NCEP ATP III criteria. The cutoff values for 
TGs and HDL-C are the main difference between the NCEP 
ATP III and Weiss et al’s12 definition. Results of this study 
demonstrated that the prevalence of MS found when using 
the NCEP ATP III definition was higher than when using 
the definition by Weiss et al.12 One of the reasons for these 
differences could be that lipid profile and BP criteria are 
higher in the NCEP ATP III definition than in the definition 
by Weiss et al.12
NCEP ATP III criteria do not include a measure of IR, 
which has been shown to provide incremental information 
in assessing cardiovascular disease risk in the nondiabetic 
  population.55 NCEP ATP III criteria have been adapted for US 
children and adolescents; other populations may have differ-
ent normal reference ranges for criteria of the definition.56–59 
In the NCEP ATP III definition, a unique cutoff value for 
TGs and HDL-C is used that may lead to misclassification 
of dyslipidemia. Age- and sex-specific fluctuation in lipid 
values is a characterization of this life period56–58 that has been 
less valued in NCEP ATP III criteria than other criteria. In 
the present study the largest disagreement between the two 
definitions used was found for HDL-C.
As there is not a standardized and internationally accepted 
definition for pediatric MS, it is difficult to compare the 
pediatric and adolescent MS frequencies reported in dif-
ferent countries.13 Not only discrepancies in the definition 
of individual components of the syndrome but also normal 
thresholds used in different studies can have an impact on 
the identification of MS prevalence.15
The evaluation of risk factors is more complicated in 
children, because of the requirement for age- and sex-
  appropriate values that may lead to less frequent identification 
of the   syndrome.17 The literature is limited with regard to the 
usefulness of the identification of MS in adolescents, as the 
diagnosis of MS is more complicated in this age group.
The most important limitation of the present study is its 
cross-sectional design. The selection of cases was based on 
referred children and adolescents, which appears as a limitation 
but, with respect to an increasing prevalence of obesity, as it 
highlights the importance of screening of metabolic risk factors 
in this population it also becomes a strength of the study.
Doubts and discussions exist about which criteria to use. 
The prevalence of MS varied according to the diagnostic cri-
teria used. The higher prevalence was detected by the NCEP 
ATP III criteria, the parameters of which include higher cut-
off values for HDL and TGs, and therefore the NCEP ATP III 
criteria are able to diagnose a larger number of children and 
adolescents at metabolic risk.
Conclusion
The prevalence of MS in children and adolescents depends on 
the criteria chosen and their respective cutoff points. To avoid 
possible under- or overestimation of the prevalence of MS, the 
use of nationwide specific cutoff values would be helpful and 
seems likely to give more reliable results. The samples in this 
study were from clinic-based series of overweight and obese 
children and adolescents seeking medical care; a survey with 
comparable methodology on national populations, in order to 
assess obesity and MS prevalence in youth, should be taken.
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